№ files_lp_4_process_2_48654
File format: docx Character count: 42238 File size: 80 KB
Year: 2026
Field: Biotechnology / Pharmacology
Document type: Research article
Institution: Mersana Therapeutics
Authors: Aleksandr Yurkovetskiy, Natalya Bodyak, Mao Yin, Joshua D. Thomas, Susan M. Clardy, Patrick R. Conlon, Cheri A. Stevenson, Alex Uttard, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter-Ovaneysan, Charlie Bu, Alex Johnson, Venu R. Gurijala, Dennis McGillicuddy, Michael J. DeVit, Laura L. Poling, Marina Protopopova, Ling Xu, Qingxiu Zhang, Peter U. Park, Donald A. Bergstrom, Timothy B. Lowinger
Keywords: Antibody-drug conjugate, polymer, bystander effect, auristatin
Target organism: Human HER2-positive and low-HER2-expression tumors
Experimental models: Mice, rats, cynomolgus monkeys
Payload: Auristatin F-hydroxypropylamide
Drug-antibody ratio (DAR): 10–15
Comparative analysis: Trastuzumab-Dolaflexin vs ado-trastuzumab emtansine
Safety evaluation: Pharmacokinetics, tumor regressions, toxicity profile
Description: Original research article detailing the synthesis, characterization, and in vivo evaluation of Dolaflexin, an auristatin-based antibody-drug conjugate with a high drug-antibody ratio and controlled bystander effect, including comparative studies with existing ADC platforms.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments
Note: Year
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers
Note: Year
ESSAY: The Bystander Effect by Dorothy Barkin
Year: 2016
Region / City: New York City, USA
Topic: Psychology, Social Behavior
Document Type: Essay
Author: Dorothy Barkin
Target Audience: Students, Researchers, General Public
Period of Application: Ongoing
Date of Approval: Not specified
Date of Changes: Not specified
Active Bystander Champion Information and Role Description
Year: 2026
Region / City: Nottingham and Nottinghamshire
Topic: Workplace culture and inclusion
Document Type: Role description / guidance
Organization: Nottingham and Nottinghamshire ICS
Author: Not specified
Target Audience: Staff interested in becoming Active Bystander Champions
Implementation Period: 6 months
Approval Date: Not specified
Training Duration: 1 day workshop plus up to 5 virtual action learning sets and 48 hours self-directed learning
Role Responsibilities: Intervene in unacceptable workplace behaviour, promote inclusivity, model ethical and respectful conduct
Support Requirements: Line manager approval for time release, engagement with Organisational Lead
Community Engagement: Participation in Community of Practice, coaching, mentoring, and learning events
Evaluation: Programme learning collated anonymously and shared with ICS and regional/national leads
Topics: Dolaflexin antibody-drug Bystander